Advisory Committee on Immunization Practices (ACIP), 20163-20164 [2021-07979]
Download as PDF
<![CDATA[
20163
Federal Register / Vol. 86, No. 72 / Friday, April 16, 2021 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
Health
Health
Health
Health
Health
Health
Departments
Departments
Departments
Departments
Departments
Departments
Average
burden per
response
(in hours)
Total annual
burden
(in hours)
......
......
......
......
......
......
Viral Hepatitis Case Report Form ........................
APR: Component 1 ..............................................
APR: Component 2 ..............................................
APR: Component 3 ..............................................
Initial Outbreak Report Form ...............................
Outbreak Summary Report Form ........................
51
59
59
14
59
59
381
1
1
1
2
2
20/60
1
1
1
20/60
20/60
6,477
59
59
14
39
39
Total .......................
..............................................................................
........................
........................
........................
6,688
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–07838 Filed 4–15–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2021–0042]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. The meeting will be webcast live
via the World Wide Web.
DATES: The meeting will be held on
April 14, 2021, from 1:30 p.m. to 4:30
p.m., EDT (dates and times subject to
change, see the ACIP website for
updates: https://www.cdc.gov/vaccines/
acip/). Written comments
must be received on or before April 16,
2021.
ADDRESSES: For more information on
ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/
index.html.You may submit comments,
identified by Docket No. CDC–2021–
0042 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
SUMMARY:
jbell on DSKJLSW7X2PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Form name
VerDate Sep<11>2014
19:57 Apr 15, 2021
Jkt 253001
MS H24–8, Atlanta, GA 30329–4027,
Attn: April 14, 2021 ACIP Meeting
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, GA 30329–
4027; Telephone: 404–639–8367; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 41 CFR 102–3.150(b),
less than 15 calendar days’ notice is
being given for this meeting due to the
exceptional circumstances of the
COVID–19 pandemic and rapidly
evolving COVID–19 vaccine
development and regulatory processes.
The Secretary of Health and Human
Services has determined that COVID–19
is a Public Health Emergency. A notice
of this ACIP meeting has also been
posted on CDC’s ACIP website at: https://
www.cdc.gov/vaccines/acip/.
In addition, CDC has sent notice of this
ACIP meeting by email to those who
subscribe to receive email updates about
ACIP.
PURPOSE: The committee is charged
with advising the Director, CDC, on the
use of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the Director of the
Centers for Disease Control and
Prevention and appear on CDC
immunization schedules must be
covered by applicable health plans.
MATTERS TO BE CONSIDERED: The
agenda will include discussions on
Janssen (Johnson & Johnson) COVID–19
Vaccine Safety. A recommendation
vote(s) is scheduled. Agenda items are
subject to change as priorities dictate.
For more information on the meeting
agenda visit https://www.cdc.gov/
vaccines/acip/meetings/meetingsinfo.html.
Meeting Information: The meeting
will be webcast live via the World Wide
Web; for more information on ACIP
please visit the ACIP website: https://
www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
E:\FR\FM\16APN1.SGM
16APN1
20164
Federal Register / Vol. 86, No. 72 / Friday, April 16, 2021 / Notices
Written Public Comment: Written
comments must be received on or before
April 16, 2021.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the April 14, 2021
ACIP meeting must submit a request at
https://www.cdc.gov/vaccines/acip/
meetings/ according to the instructions
provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by 12:00 p.m., EDT, April 14, 2021. To
accommodate the significant interest in
participation in the oral public
comment session of ACIP meetings,
each speaker will be limited to 3
minutes, and each speaker may only
speak once per meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–07979 Filed 4–14–21; 11:15 am]
jbell on DSKJLSW7X2PROD with NOTICES
BILLING CODE 4163–18–P
VerDate Sep<11>2014
19:57 Apr 15, 2021
Jkt 253001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–21–21EJ; Docket No. CDC–2021–
0038]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled SimpleReport Mobile Application.
SimpleReport is a free web-based
application that provides an easy way to
manage the testing workflow, to record
results for rapid point of care COVID
tests, to report the results to the
appropriate public health department
on behalf of the testing site, and to
comply with existing requirements.
DATES: CDC must receive written
comments on or before June 15, 2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2021–
0038 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
SUMMARY:
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
D74, Atlanta, Georgia 30329; phone:
404–639–7118; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
SimpleReport Mobile Application—
New—Office of Science (OS), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
SimpleReport is a free web-based
application that provides an easy way to
manage the testing workflow, to record
results for rapid point of care COVID
tests, to report the results to the
appropriate public health department
on behalf of the testing site, and to
comply with existing requirements. The
data collected through this application
is crucial for public health departments
to take action during the current health
crisis. Currently, many point of care
E:\FR\FM\16APN1.SGM
16APN1
]]>Agencies
[Federal Register Volume 86, Number 72 (Friday, April 16, 2021)]
[Notices]
[Pages 20163-20164]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-07979]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2021-0042]
Advisory Committee on Immunization Practices (ACIP)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC), announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. The meeting will be webcast
live via the World Wide Web.
DATES: The meeting will be held on April 14, 2021, from 1:30 p.m. to
4:30 p.m., EDT (dates and times subject to change, see the ACIP website
for updates: https://www.cdc.gov/vaccines/acip/). Written
comments must be received on or before April 16, 2021.
ADDRESSES: For more information on ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/.You may submit comments,
identified by Docket No. CDC-2021-0042 by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027, Attn: April 14, 2021
ACIP Meeting
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE, MS-H24-8, Atlanta, GA 30329-4027; Telephone: 404-639-8367;
Email: [email protected].
SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102-3.150(b), less
than 15 calendar days' notice is being given for this meeting due to
the exceptional circumstances of the COVID-19 pandemic and rapidly
evolving COVID-19 vaccine development and regulatory processes. The
Secretary of Health and Human Services has determined that COVID-19 is
a Public Health Emergency. A notice of this ACIP meeting has also been
posted on CDC's ACIP website at: https://www.cdc.gov/vaccines/acip/. In addition, CDC has sent notice of this ACIP meeting by
email to those who subscribe to receive email updates about ACIP.
PURPOSE: The committee is charged with advising the Director, CDC,
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s,
the committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children (VFC) program,
along with schedules regarding dosing interval, dosage, and
contraindications to administration of vaccines. Further, under
provisions of the Affordable Care Act, section 2713 of the Public
Health Service Act, immunization recommendations of the ACIP that have
been approved by the Director of the Centers for Disease Control and
Prevention and appear on CDC immunization schedules must be covered by
applicable health plans.
MATTERS TO BE CONSIDERED: The agenda will include discussions on
Janssen (Johnson & Johnson) COVID-19 Vaccine Safety. A recommendation
vote(s) is scheduled. Agenda items are subject to change as priorities
dictate. For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
Meeting Information: The meeting will be webcast live via the World
Wide Web; for more information on ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
[[Page 20164]]
Written Public Comment: Written comments must be received on or
before April 16, 2021.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the April 14, 2021 ACIP meeting must submit a
request at https://www.cdc.gov/vaccines/acip/meetings/ according to the
instructions provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by 12:00 p.m., EDT, April 14, 2021. To accommodate the
significant interest in participation in the oral public comment
session of ACIP meetings, each speaker will be limited to 3 minutes,
and each speaker may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-07979 Filed 4-14-21; 11:15 am]
BILLING CODE 4163-18-P
